期刊
CANCER GENETICS
卷 266, 期 -, 页码 1-6出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cancergen.2022.05.001
关键词
BRAF; Non-small-cell lung cancer; MD simulation
In this study, the sensitivity of BRAF tyrosine kinase inhibitor mechanism in patients with rare BRAF compound mutation was clarified and predicted using genetic analysis and computational simulation model. The results demonstrated the importance of constructing a genomic and simulation fused database for the development of personalized medicine in this field.
Purpose: The present study clarified the sensitivity of the BRAF tyrosine kinase inhibitor mechanism in patients with BRAF compound mutation and predicted the sensitivity using molecular dynamics simulation.Methods: We examined 16 BRAF tumors with p.V600E-positive non-small-cell lung cancer.Results: One patient (6.2%) had a BRAF p.V600E and p.K601_W604 compound mutation with a good clinical response to dabrafenib and trametinib. Molecular dynamics simulation also complemented the effect.Conclusions: The combination of a genetic analysis and computational simulation model may help predict the sensitivity for dabrafenib in cases with a rare BRAF compound mutation. The construction of a genomic and simulation fused database is important for the development of personalized medicine in this field.(c) 2022 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据